Canopy Growth Completes MTL Cannabis Acquisition, Creating Canada’s Leading Medical Cannabis Platform

Canopy Growth Corporation (CGC ) has officially completed its acquisition of MTL Cannabis Corp., marking a significant consolidation in Canada’s evolving cannabis sector. The deal positions the combined entity as the country’s leading medical cannabis business by revenue, while strengthening Canopy’s ambitions for international expansion.

The transaction brings together two complementary operators: Canopy’s global footprint and brand portfolio with MTL’s reputation for high-quality, craft-focused cannabis production. With the integration now underway, the company is aiming to accelerate its path toward sustainable profitability while expanding its reach across both domestic and international markets.

Building Scale in Medical Cannabis

The acquisition significantly enhances Canopy Growth’s position in Canada’s medical cannabis segment. By integrating MTL’s patient network, clinic infrastructure, and digital distribution channels, the company now holds the top market share in the country based on revenue.

MTL’s assets—including Canada House clinics and its ABBA Medix platform—add direct-to-patient capabilities that strengthen Canopy’s ability to serve medical users nationwide. This vertical integration is increasingly important in a market where patient access, product consistency, and regulatory compliance remain key differentiators.

At the same time, the deal reinforces Canopy’s supply chain with a steady stream of premium flower, a category that continues to dominate both medical and adult-use demand.

Strengthening Supply for Global Growth

Beyond Canada, the acquisition is closely tied to Canopy’s international ambitions. The company has been expanding its presence in regulated medical markets, particularly in Europe, where demand for pharmaceutical-grade cannabis continues to grow.

MTL’s cultivation and post-harvest capabilities provide Canopy with greater control over product quality and consistency—critical factors for exporting into tightly regulated international markets. The additional supply is expected to support rising demand while reducing reliance on external sources.

This move reflects a broader industry shift toward vertically integrated operations that can meet both domestic and export requirements with standardized, high-quality production.

Québec Expansion and Adult-Use Momentum

The deal also deepens Canopy’s footprint in Québec, Canada’s second-largest cannabis market. MTL’s established operations and brand portfolio in the province give Canopy a stronger competitive position in both medical and adult-use segments.

MTL has built a loyal following in the “upper-mainstream” category, particularly in flower and pre-rolls. These products are expected to complement Canopy’s existing lineup, improving shelf presence and distribution across key provinces.

As competition intensifies in Canada’s adult-use market, brand strength and product consistency are becoming increasingly important. The integration of MTL’s offerings could help Canopy better compete in these high-volume categories.

Financial Impact and Path to Profitability

A key aspect of the acquisition is MTL’s status as a profitable, cash-generating business. Unlike many cannabis operators that continue to struggle with margins, MTL brings disciplined cost management and operational efficiency.

Canopy expects to realize approximately $10 million in run-rate synergies within 18 months, driven by supply chain integration, operational efficiencies, and expanded distribution.

More importantly, the transaction supports Canopy’s broader objective of achieving positive adjusted EBITDA by fiscal 2027. In an industry that has faced persistent financial challenges, this signals a shift toward consolidation and profitability over rapid expansion.

Leadership Integration and Operational Depth

The acquisition is not just about assets—it also brings key leadership into Canopy Growth’s executive team. Former MTL CEO Mike Perron has joined as Chief Operating Officer, while co-founders Richard Clément and Michel Clément will serve as strategic advisors.

This integration adds expertise in cultivation, genetics, and facility operations, areas where MTL has built a strong reputation. Retaining this knowledge base is expected to play a critical role in maintaining product quality while scaling operations.

The combined leadership team reflects a blend of operational discipline and global ambition, positioning the company for more consistent execution moving forward.

Transaction Details

Under the terms of the deal, Canopy Growth acquired 100% of MTL’s outstanding shares. Shareholders received 0.32 Canopy shares plus $0.144 in cash per MTL share.

In total, Canopy issued approximately 41.2 million shares and paid around $18.5 million in cash as part of the transaction. MTL Cannabis is now a wholly owned subsidiary, and its shares are expected to be delisted from the Canadian Securities Exchange.

Industry Implications

The acquisition highlights a broader trend in the cannabis industry: consolidation among operators seeking scale, efficiency, and profitability. As regulatory frameworks mature and international opportunities expand, companies with strong supply chains and operational discipline are gaining an advantage.

For Canopy Growth, this deal represents more than just an expansion—it signals a strategic pivot toward building a sustainable, globally competitive cannabis business anchored in legal medical markets.

As the industry continues to evolve, the success of this integration could serve as a blueprint for how cannabis companies transition from growth-at-all-costs to long-term financial stability.